CYT#

Related by string. * * CYT# QbG# . 2 inhibitor CYT# . CYT# novel . CYT# vascular disrupting . CYT# potent vascular disrupting . CYT# NicQb . JAK#/JAK# inhibitor CYT# *

Related by context. Frequent words. (Click for all words.) 70 MGCD# [001] 66 INCB# [002] 66 AP# [003] 66 ISIS # 66 MGCD# [002] 65 Atiprimod 64 ZYBRESTAT 64 antiviral activity 64 perifosine 64 pharmacodynamic 64 Phase Ib 64 tolerability profile 64 bavituximab 64 XL# [003] 63 tolerability 63 antitumor activity 63 eculizumab 63 Perifosine 63 Phase 1b 63 Alpharadin 63 PF # [001] 63 Phase IIa trial 63 ADVEXIN 62 RDEA# 62 HspE7 62 elesclomol 62 IMGN# 62 nimotuzumab 62 pralatrexate 62 PLX# 62 ACTEMRA 62 Marqibo 62 Phase IIa clinical 62 ANA# 61 dose escalation 61 FTY# 61 MDV# 61 vandetanib 61 monotherapy 61 pharmacokinetic profile 61 sunitinib 61 RG# [001] 61 immunogenicity 61 anti angiogenic 61 Phase 2a clinical 61 pharmacokinetic 61 bortezomib 61 preclinical studies 61 Tovaxin 61 TB4 60 tivozanib 60 raltegravir 60 Bronchitol 60 G CSF 60 Phase 2b clinical 60 dasatinib 60 CTCE 60 voreloxin 60 telbivudine 60 ENMD 60 daclizumab 60 CRx 60 Locteron 60 ALN RSV# 60 BiovaxID 60 etanercept 60 hematologic malignancies 60 LymphoStat B 59 AZD# 59 IDX# 59 AEZS 59 TREANDA 59 REVLIMID 59 Denosumab 59 dosing regimens 59 kinase inhibitor 59 preclinical models 59 HDAC inhibitors 59 dose limiting toxicities 59 Zerenex 59 golimumab 59 Preclinical studies 59 FOLOTYN 59 ALKS 59 GM CSF 59 Xcytrin 59 PBT2 59 Phase 2b study 59 pharmacodynamics 58 T DM1 58 docetaxel 58 potent inhibitor 58 cutaneous T cell 58 CUDC 58 gefitinib 58 TMC# [001] 58 Phase 2b trial 58 PMX # 58 monoclonal antibody 58 preclinical 58 HRPC

Back to home page